GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from ...

London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa.

The UK big pharma company will pay $1.2bn upfront for Boston’s subsidiary BP Asset IX, which will give the company access to efimosfermin. GSK has also agreed to pay additional milestone ...

GSK will acquire liver-disease treatment efimosfermin from Boston Pharmaceuticals for up to $2 billion to expand its portfolio. The British pharma giant said Wednesday that it will pay the U.S ...

GSK plc (LSE/NYSE: GSK) and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, ...

The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...

GSK will acquire the liver disease drug efimosfermin from Boston Pharmaceuticals in a deal worth up to $2 billion, The Wall Street Journal reported May 14. The agreement includes a $1.2 billion ...

Only a few days out of the European Association for the Study of the Liver annual meeting, the metabolic dysfunction-associated steatohepatitis (MASH) space continues to grab headlines, with GSK plc ...